10–20 days
Community course convention, not a clinical study period.
Protocol / Research Dosing Guide
Cortagen Dosage Guide: Community Schedule and Evidence
An evidence-organized Cortagen guide separating AEDP preclinical work from Cortexin evidence and community protocols.
Last reviewed September 15, 202618 minute readResearch information only
Level 2 — Preclinical evidenceNo human dose-finding trialsNot FDA approved
Cortagen Quick Start
Cortagen is the synthetic tetrapeptide Ala-Glu-Asp-Pro. Its direct evidence is limited to animal and laboratory work from a narrow research base. Human studies of the different porcine extract Cortexin do not validate Cortagen.
Why researchers care
Cortical-neuron and nerve-regeneration research
Class
Synthetic AEDP tetrapeptide bioregulator
Route reported
Subcutaneous or intramuscular use is community reported
Cycle length
10–20 days reported; not validated
Regulatory status
Research-use listing; not FDA approved
Loading supplier information
Cortagen Dosing Protocol and Schedule
The supplied source reports 0.5–2 mg once daily for 10–20 days by subcutaneous or intramuscular routes. Every value is vendor/community reported, not a clinical dose-finding result.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Community low | 0.5 mg daily | 10–20 days; unvalidated |
| Community common | 1 mg daily | 10–20 days; unvalidated |
| Community high | 2 mg daily | 10–20 days; unvalidated |
No validated human amount, route, frequency, course length, repeat interval, or rest period exists for synthetic Cortagen.
Cortagen Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured diluent volume
Research planning item
U-100 measurement reference
Research planning item
Alcohol swabs
Research planning item
Appropriate sharps container
Research planning item
Written concentration label
Cortagen Reconstitution Calculator
Vial-format concentration math
Concentration
10 mg/mL
Draw volume
0.1 mL
U-100 units
10
Mathematical draws
20
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take Cortagen: Morning or Night?
Once daily
Community convention only.
Morning or evening
Not established.
With food
Not applicable to reported injection routes and not established.
Missed amount
No validated procedure exists.
Cortagen Route Comparison
| Route | Evidence context | Boundary |
|---|---|---|
| Subcutaneous | Community reported | No human route trial |
| Intramuscular | Community reported | Often conflated with Cortexin |
| Laboratory exposure | Cell and tissue studies | Not human dosing |
| Cortexin | Different porcine extract | Not interchangeable |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
Cortagen Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Human half-life | Not established | No human PK study |
| Animal half-life | Not established | No PK study identified |
| Bioavailability | Not established | No route-specific exposure data |
| Frequency | Daily is community reported | Not trial derived |
Cortagen Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous | 0.5 mg | Once daily | Community report | No |
| Subcutaneous or intramuscular | 1 mg | Once daily | Community report | No |
| Subcutaneous or intramuscular | 2 mg | Once daily | Community report | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
Cortagen Reconstitution Guide
Concentration: 10 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 1 mg | 0.1 mL | 10 units |
| 2 mg | 0.2 mL | 20 units |
| 3 mg | 0.3 mL | 30 units |
- 1.Confirm the exact vial label and total quantity.
- 2.Record the measured diluent volume.
- 3.Clean the vial stopper.
- 4.Add liquid slowly along the vial wall.
- 5.Swirl gently; do not shake.
- 6.Inspect for cloudiness, discoloration, or particles.
- 7.Label the calculated concentration and preparation date.
- 8.Use the result only for arithmetic, not as a recommendation.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How Cortagen Works
AEDP sequence
Cortagen is Ala-Glu-Asp-Pro.
Cortagen Human Trials and FDA Status
Current status · verified September 15, 2026
Research-use listing; not FDA approved
- No controlled human Cortagen trial was identified.
- Rat and tissue-culture studies examined nerve regeneration and cortical cells.
- Direct work is old and concentrated within the originating research group.
- Independent replication is limited.
- Cortexin clinical reports involve a different multi-peptide extract.
Who Should Avoid Cortagen?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No safety data
Children or adolescents
No safety data
Neurologic disease needing diagnosis
No established clinical use
Known ingredient sensitivity
Potential allergic risk
Concurrent medicines
No interaction studies
Long-term or repeated use
No safety data
Cortagen Side Effects, Risks and Safety
Injection-site redness or sorenessCommunity reported
Important limitation: No controlled incidence.
Systemic adverse effectsUnknown
Important limitation: No human safety dataset.
Immune reactionUnknown
Important limitation: No immunogenicity study.
Neurologic effectsUnknown
Important limitation: No controlled human assessment.
Drug interactionsUnknown
Important limitation: No interaction studies.
Long-term effectsUnknown
Important limitation: No follow-up evidence.
Cortagen Timeline and Monitoring
Repeat courses
Community reported; no restart criteria.
Clinical response
Not established in humans.
Monitoring
No validated biomarker panel or stopping rule exists.
Cortagen Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Nerve regeneration | Level 2 — preclinical | Rat model | No human confirmation |
| Cortical-neuron effects | Laboratory evidence | Tissue culture | Clinical meaning unknown |
| Gene-expression regulation | Preclinical hypothesis | Limited research group | No human validation |
| Cognitive benefit | Not established | Often conflated with Cortexin | Different product |
Cortagen Storage and Handling
Unreconstituted vial
No Cortagen-specific stability study was identified.
Prepared vial
Community 2–8°C and 28-day guidance is not validated stability evidence.
Cortexin product
Different formulation and handling; not transferable.
Appearance
Visual inspection cannot establish purity or sterility.
Cortagen Troubleshooting
Cortexin evidence appears
Do not assign it to synthetic Cortagen.
Units look wrong
Recheck vial mg, liquid mL, target mg, and U-100 conversion.
A clinical benefit is claimed
No controlled human Cortagen trial exists.
Product testing is pending
Do not describe the current batch as verified.
A scheduled amount is missed
No validated procedure exists.
Cortagen Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| Cortagen | Synthetic AEDP tetrapeptide | Preclinical evidence | Not approved |
| Cortexin | Porcine cortical polypeptide extract | Separate human literature | Different product |
| Cerebrolysin | Porcine peptide/amino-acid mixture | Mixed randomized evidence | Different product |
| Pinealon | Short peptide bioregulator | Limited preclinical evidence | Not approved |
Cortagen Frequently Asked Questions
What is Cortagen?
The synthetic tetrapeptide Ala-Glu-Asp-Pro.
Is it Cortexin?
No.
Is it FDA approved?
No.
Are there human trials?
No controlled human Cortagen trial was identified.
What is its half-life?
Not established.
Is injection validated?
No; routes are community reported.
Is the 10-to-20-day course validated?
No.
Can Cortexin evidence be transferred?
No.
Is long-term safety known?
No.
What does the calculator do?
It performs concentration and volume arithmetic only.
Sources and Research
Coverage source
1. Cortagen dosing guide
Community schedule and explicit Cortagen-versus-Cortexin boundary.
Open direct sourceAnimal research
2. Cortagen and peripheral nerve regeneration
Preclinical rat research; not human dosing evidence.
Open direct sourcePreclinical review
3. Short peptide regulation review
Mechanistic and preclinical context for peptide bioregulators.
Open direct sourceMissing information flagged for review
- Controlled human evidence: Not established
- Human dose and route: Not established
- Human and animal pharmacokinetics: Not established
- Validated cycle and rest period: Not established
- Compound-specific stability: Not established
- Human safety and interactions: Not established
- Independent replication: Not established